Immatics (IMTX) Non Operating Income (2019 - 2025)
Immatics recorded quarterly Non Operating Income of $3.9 million in Q4 2025, down 16.62% quarter-over-quarter from $4.6 million in Q3 2025, and down 91.47% year-over-year from $45.3 million in Q4 2024.
Immatics' Non Operating Income history runs 7 years deep, the most recent figure standing at $3.9 million for Q4 2025.
- In Q4 2025, Non Operating Income fell 91.47% year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at -$17.9 million (down 127.84% YoY), while the FY2025 annual figure was -$18.6 million, down 128.95% from the prior year.
- Non Operating Income came in at $3.9 million for Q4 2025 at Immatics, down from $4.6 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $45.3 million in Q4 2024 to a low of -$20.6 million in Q2 2025.
- A 5-year average of $2.9 million and a median of $1.6 million in 2022 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income plunged 1182.94% in 2022 and jumped 2587.02% in 2024, its largest moves.
- Immatics' Non Operating Income stood at -$831666.9 in 2021, then slumped by 1182.94% to -$10.7 million in 2022, then surged by 115.79% to $1.7 million in 2023, then surged by 2587.02% to $45.3 million in 2024, then tumbled by 91.47% to $3.9 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $3.9 million, $4.6 million, and -$20.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | 3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.86 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | -20.63 Mn |
| Mar 31, 2025 | -5.76 Mn |
| Dec 31, 2024 | 45.27 Mn |
| Sep 30, 2024 | -3.15 Mn |
| Jun 30, 2024 | 9.38 Mn |
| Mar 31, 2024 | 12.76 Mn |
| Dec 31, 2023 | 1.68 Mn |
| Sep 30, 2023 | 7.38 Mn |
| Jun 30, 2023 | -11.21 Mn |
| Mar 31, 2023 | 7.17 Mn |
| Dec 31, 2022 | -10.67 Mn |
| Sep 30, 2022 | 1.56 Mn |
| Jun 30, 2022 | 4.08 Mn |
| Mar 31, 2022 | 19.27 Mn |
| Dec 31, 2021 | -831,666.88 |
| Sep 30, 2021 | -4.96 Mn |
| Jun 30, 2021 | -3.78 Mn |
| Mar 31, 2021 | 1.24 Mn |
| Dec 31, 2020 | 2.46 Mn |
| Sep 30, 2020 | -169.56 Mn |
| Jun 30, 2020 | -1.90 Mn |
| Mar 31, 2020 | 2.98 Mn |
| Dec 31, 2019 | 4.10 Mn |
| Sep 30, 2019 | 3.10 Mn |
| Jun 30, 2019 | -400,015.52 |